Application of miRNA in preparation of medicine for treating AD, medicine composition and application of medicine composition

A composition and drug technology, applied in the application of drugs, in the field of preparation of therapeutic drugs, can solve problems such as brain tissue damage, Aβ antibody can not reach the therapeutically effective endpoint index, failure, etc.

Pending Publication Date: 2022-05-13
SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, many Aβ antibodies have failed in clinical trials either because they could not meet the therapeutically effective endpoints or because of side effects such as cerebral edema and hemorrhage.
This suggests that Aβ may not only be the cause of AD disease but also lead to the emergence of other pathological processes independent of Aβ and then promote the progression of AD disease. Real benefits in cognition and daily living, but with adverse effects of brain tissue damage causing cerebral edema and amyloid-related cerebral microbleeds

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of miRNA in preparation of medicine for treating AD, medicine composition and application of medicine composition
  • Application of miRNA in preparation of medicine for treating AD, medicine composition and application of medicine composition
  • Application of miRNA in preparation of medicine for treating AD, medicine composition and application of medicine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0018] In order to understand the technical content of the present invention more clearly, the following examples are given in detail.

[0019] The applicant's research found that the levels of miR-1185-2-3p and miR-107 were abnormal in the peripheral plasma of early AD patients, and cell experiments confirmed that regulating the levels of these miRNAs in cells can effectively regulate the levels of intracellular BACE1 and Aβ. A major obstacle to combining miRNAs as AD therapeutics is the stability, targeting, blood-brain barrier penetration and biodistribution of exogenous miRNAs in vivo. The adeno-associated virus (AAV) vector is considered as a vector due to its good safety, wide range of host cells, low immunogenicity, long-term stable expression of foreign genes in the body, and the relatively specificity of different serotypes infecting different organs and tissues. One of the most promising gene transfer vectors, widely used in gene therapy and vaccine research worldwid...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of miRNA (micro Ribonucleic Acid) in preparation of a medicine for treating an Alzheimer's disease (AD), and the miRNA is composed of one or two of miR-1185-2-3p and miR-107. The invention also relates to an application of the miRNA in preparation of the medicine for treating the Alzheimer's disease (AD), and the miRNA is composed of one or two of miR-1185-2-3p and miR-107. The invention also relates to a corresponding pharmaceutical composition and application thereof. The miRNA has the beneficial effects that the single miRNA and the combination thereof which have relatively high treatment value on AD are found for the first time, so that the possibility of carrying out early treatment on AD pathogenesis in the genetic regulation field is realized, and the early intervention on AD pathogenesis is facilitated.

Description

technical field [0001] The present invention relates to the technical field of early treatment of Alzheimer's disease, in particular to the technical field of methods for preparing therapeutic drugs, and specifically refers to the application of miRNA in the preparation of drugs for treating AD, pharmaceutical compositions and applications thereof. Background technique [0002] Alzheimer's disease (AD), commonly known as senile dementia, is a neurofibrillary tangle formed by the deposition of amyloidβ-protein (Aβ) in the brain and the disorder of microtubule structure caused by hyperphosphorylated Tau protein. Neurodegenerative disease as the main pathological feature. AD is a chronic, non-infectious, age-related disease of complex etiology and is the most prevalent form of dementia, accounting for 50-60% of all cases. With an aging population, AD has become a common, frequently occurring, and high-burden disease. Alzheimer's Disease International (ADI) estimates that ther...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61P25/28
CPCA61K48/005A61K48/0008A61P25/28
Inventor 王涛柳安
Owner SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap